Loading clinical trials...
Loading clinical trials...
The goal of this observational study is to investigate the relationship between structural brain changes and psychiatric comorbidities in individuals diagnosed with eating disorders (EDs). The main question it aims to answer is: How are structural brain volumetric changes associated with psychiatric comorbidities in patients with eating disorders? Participants with a clinical diagnosis of an eating disorder will undergo brain MRI scans for volumetric analysis and structured psychiatric assessments to identify comorbid conditions. Data will be collected cross-sectionally from patients receiving routine clinical care, with the aim of identifying neurobiological and psychiatric patterns that could inform targeted treatment and prevention strategies.
Eating disorders (EDs) are complex psychiatric conditions characterized by persistent disturbances in eating behaviors, body weight regulation, and self-perception, often accompanied by severe physical health consequences and high mortality rates (1). They typically emerge during adolescence or early adulthood but may develop at any age, with a multifactorial etiology involving genetic, neurobiological, psychological, and sociocultural influences (2). The main diagnostic categories include anorexia nervosa (AN)-marked by significantly low body weight, intense fear of weight gain, and body image distortion; bulimia nervosa (BN)-characterized by recurrent binge eating followed by compensatory behaviors such as vomiting, fasting, or excessive exercise; and binge-eating disorder (BED)-involving recurrent episodes of excessive food intake without compensatory behaviors (3). Other specified feeding or eating disorders (OSFED) encompass clinically significant presentations not meeting full criteria for the above disorders. In Egypt, eating disorders represent an under-recognized public health concern. Recent epidemiological studies have found that approximately 13.3% of Egyptian youth meet criteria for an ED, with BN being the most prevalent (8.4%) and BED affecting 1.4% (4). The apparent absence of AN cases in some surveys may reflect cultural perceptions of thinness, under-diagnosis, and stigma rather than true absence (5). Risk factors identified in Egyptian samples include high body mass index (BMI), exposure to Westernized beauty ideals, depression, and a history of psychological trauma (6). Structural neuroimaging, particularly MRI, has revealed consistent alterations in ED patients. AN is often associated with global and regional gray matter reductions-particularly in the parietal, frontal, and temporal cortices-along with decreased subcortical and cerebellar volumes (7). BN has been linked to structural changes in frontal and striatal regions, potentially reflecting alterations in impulse control and reward processing (8). Some volumetric changes may partially reverse with nutritional rehabilitation, suggesting neuroplasticity (9). Psychiatric comorbidities are highly prevalent in EDs, affecting more than 70% of patients (10). Anxiety disorders, mood disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and substance use disorders are common, often worsening symptom severity and complicating treatment (10, 11). OCD traits are especially frequent in AN, while BN shows strong associations with depression and anxiety. This study aims to use structural MRI to investigate brain volumetric changes in individuals with eating disorders and to explore the relationship between these changes and psychiatric comorbidities, thereby contributing to a more comprehensive understanding of the neuropsychiatric profile of EDs.
Age
13 - 60 years
Sex
ALL
Healthy Volunteers
Yes
Start Date
December 10, 2025
Primary Completion Date
February 20, 2027
Completion Date
May 20, 2027
Last Updated
August 20, 2025
80
ESTIMATED participants
Lead Sponsor
Assiut University
NCT06306586
NCT07179068
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07146503